Navigation Links
Revolutionary Healing Technology for Treating Difficult and Chronic Wounds Approved by Health Canada
Date:6/6/2008

TORONTO, June 6 /PRNewswire/ - Archimed, the woundcare division of Insense Ltd., today announced it has received approval from Health Canada for the use of its revolutionary Oxyzyme product in the treatment of difficult and chronic wounds. Oxyzyme was first trialed in Toronto by Dr. Gary Sibbald, one of the world's leading wound care specialists, in 2004 by his team at the Toronto Wound Healing Centres. The announcement was made at the 3rd Congress of the World Union of Wound Healing Societies taking place from June 4-8, 2008 at the Metro Toronto Convention Center.

Oxyzyme is a biochemical system in a dressing that ensures the oxygen in the wound environment meets the diverse oxygen needs of the cells responsible for healing. Ongoing clinical programs being undertaken in Europe are showing that 20% of old, previously unhealable wounds (3.5 years) are now closing in six weeks or under when dressed with Oxyzyme. Easy to use by any clinical professional, Oxyzyme will now soon be available to the Canadian health care system at a modest cost.

In conjunction with the announcement, Professor T.K. Hunt, often cited as the father of modern wound care, was awarded a lifetime achievement award by the World Union of Wound Healing Societies. Professor Hunt's insight and discoveries on the role oxygen plays in the healing process was the inspiration behind the development of Oxyzyme.

"The real value of Oxyzyme is that it combines two agents - iodine and oxygen - that are essential to the process of wound healing and provides further opportunities to overcome barriers to healing that may exist in the patient," explained Dr. Keith Harding, leading figure in the international wound care community and also a member of the World Union faculty.
For more information about Oxyzyme and Archimed visit http://www.archimed.co.uk.

About Insense Ltd.

------------------ Insense is a British biotechnology company founded by Professor Paul Davis, Chief Scientific Officer, who led the team which invented and developed the ClearBlue(TM) pregnancy test. The company is also developing products out of its core technology for dermatology and health and beauty applications. For more information about Insense Ltd. visit http://www.insense.co.uk.


'/>"/>
SOURCE Insense Ltd.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. ORF Genetics Opens Revolutionary Green Factory in Iceland
2. Israels Prestigious Presidents Conference to Feature Oramed Pharmaceuticals Revolutionary Oral Insulin Capsule
3. SimBioSys Utilizes Revolutionary Hardware Technology to Open New Frontiers in Molecular Modeling
4. NASA MidSTAR-1 successful technologies may be revolutionary
5. NEXCORE Technology Obtains Licenses for Revolutionary Fluid Management System
6. Webcam MD - Launch of revolutionary web-based medical technology
7. FDA Clears Biospace meds Revolutionary Low Dose Xray Imager
8. Cooler Solutions and Leading Research Hospital to Design Revolutionary Osteoporosis Diagnosis Device
9. Cardicas C-Port(R) Flex A Anastomosis System Allows Surgeons to Perform Revolutionary Closed-Chest Heart Bypass Surgeries
10. Revolutionary Genomics Research Group Opens Boston Office; Provides DNA Evidence in Workers Comp Cases
11. Advanced BioHealing and Regenesis Biomedical Form Co-Promotion Alliance for Dermagraft(R)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/15/2017)... ... 2017 , ... Pittcon is pleased to once again co-program ... This year’s symposium, organized by the Pittcon 2018 program chair, Annette Wilson, (University ... dynamic presentation will discuss novel ionization processes, high throughput IMS-MS technologies, and top ...
(Date:8/15/2017)... Linda, Ca (PRWEB) , ... August 15, 2017 ... ... coffee production and is threatened by various biotic and abiotic factors. During this ... complex evolutionary history of coffee, as well as gain a better understanding of ...
(Date:8/14/2017)... York, NY (PRWEB) , ... August 14, 2017 , ... ... in Clinical Trials event, which will take place on September 6, 2017 at ... Daniel Karlin, MD , Head of Experimental Medicine, Informatics, and Regulatory Strategy, Pfizer Innovative ...
(Date:8/11/2017)... ... August 11, 2017 , ... “There ... particular, more natural alternatives to synthetic ingredients,” said Matt Hundt, President of Third ... the established manufacturing presence and know-how of Biorigin will allow us to bring ...
Breaking Biology Technology:
(Date:4/3/2017)... April 3, 2017  Data captured by ... platform, detected a statistically significant association between ... to treatment and objective response of cancer ... to predict whether cancer patients will respond ... as well as to improve both pre-infusion potency ...
(Date:3/28/2017)... India , March 28, 2017 ... IP, Biometrics), Hardware (Camera, Monitors, Servers, Storage Devices), Software ... Vertical, and Region - Global Forecast to 2022", published ... Billion in 2016 and is projected to reach USD ... between 2017 and 2022. The base year considered for ...
(Date:3/23/2017)... 23, 2017 Research and Markets has announced ... & Trends - Industry Forecast to 2025" report to their ... The ... CAGR of around 8.8% over the next decade to reach approximately ... the market estimates and forecasts for all the given segments on ...
Breaking Biology News(10 mins):